About this trial
People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult.
The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine.
The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.
Eligibility criteria
Qualifiers
Adults 18+
Meeting diagnostic criteria for Fibromyalgia
Patients taking Duloxetine 60 mg/day for at least 8 weeks
Disqualifiers
Pregnant patients per verbal confirmation
Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.
Patients requiring an interpreter to communicate
Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).
Trial design
Treatments tested in this trial
- Observational